For example, multiple JAK inhibitors are approved for the treatment of autoimmune diseases as well as hematopoietic malignancies (26, 32), and autoimmune diseases commonly present in both RUNX1-FPD and MDS patients. Here, RUNX1 is linked to myelodysplastic syndrome.